National Institute of Neurological Disorders and Stroke (NINDS)

Researchers: There will be a pre-application webinar on November 19 at 2:00 p.m. ET for those interested in learning more about notice of funding opportunity (NOFO) RFA-NS-25-023 HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed). Register: https://go.nih.gov/a0r8elK This NOFO seeks to support initial translational efforts that will enable an analgesic drug discovery program for novel, non-opioid, and nonaddictive treatments for pain. Learn more: https://lnkd.in/geYq58xM #nihHEALinitiative

🗓️Planning ahead for #2024NDiSTEM? Several NINDS Staff members are heading to Phoenix for the Society for Advancement of Chicanos/Hispanics and Native Americans in Science (SACNAS) Annual Meeting! You’ll have a chance to meet Dr. Lauren Ullrich, Dr. Joe Sanchez, and Dr. Jimmy Liu in the NINDS Office of Programs to Enhance Neuroscience Workforce Diversity (OPEN), and Dr. Faith Plante in the NINDS Intramural Office of Research Training and Career Development. Stop by the NINDS booth (#605) to meet our team and learn about NIH diversity training grants and research opportunities. And save the date for our session “Pain Points: Unveiling Innovations, Careers, and Funding in Pain Research" on Nov 1 from 3:15-4:30pm MST in the Phoenix Convention Center, Rm 223! You can add the event to your calendar: https://lnkd.in/eb59DnZV

Exciting news for the neurological research community! Researchers funded by the National Institutes of Health (NIH) are developing a groundbreaking innovation for Parkinson's disease treatment: a self-adjusting brain pacemaker. This novel device leverages real-time brain activity to personalize stimulation, potentially offering continuous and more effective management of Parkinson's symptoms. Read the full story: https://go.nih.gov/sWAN8VV

Since 2006, the NIH Blueprint for Neuroscience Research has supported the NeuroImaging Tools and Resources Collaboratory (NITRC). NITRC serves as a hub for finding, developing, and sharing neuroimaging and neuroinformatics resources and as an online community for getting technical information and assistance. #NIHBlueprint20

A new study identifies a possible drug candidate for a genetic cause of ALS/FTD. An analysis of large-scale genomic data revealed that acamprosate, a medication used to treat alcohol use disorder, could potentially be repurposed to treat patients carrying C9orf72 repeat expansions. https://go.nih.gov/hNqkaDI

New Director’s Message on highlights from the September National Advisory Neurological Disorders and Stroke (NANDS) Council meeting, where we discussed new NINDS leadership, the challenging budget landscape, strategic priority setting efforts, and more. Available now: https://go.nih.gov/J64TFSn

Calling all investigators dedicated to finding new hope for ALS patients! Today at 1:30pm ET, NINDS is hosting a webinar series on the ALS Expanded Access (U01) Program. This program supports research utilizing data from expanded access trials for investigational drugs or biological products aimed at ALS patients who cannot participate in traditional clinical trials. Register now: https://go.nih.gov/xuy9PaA

The NIH HEAL Initiative® is developing a strategic plan to establish research priorities that will guide the initiative’s efforts to help individuals affected by substance use and those living with pain. This strategic plan will build on past progress and ensure that the initiative continues to evolve and provide the greatest benefit, by drawing on public input and existing research frameworks. Learn more about the strategic planning process: https://go.nih.gov/NSVHi5O HEAL invites the research community and people with lived experience with pain to provide input on the HEAL pain research priorities at a series of public workshops. Please join us and make your voice heard! Register for an upcoming workshop: https://bit.ly/40eyepi  #nihHEALinitiative

Funding Opportunity for ALS Research Clinical Trial Sites Are you a clinical trial site participating in a phase 3 ALS clinical trial? NINDS recently re-issued a funding opportunity: "Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)." This funding can support research using data from EA studies for ALS investigational drugs. Learn more and apply: https://go.nih.gov/3Yy1641

In 2021, NIH Blueprint supported the development of tools to study biomolecular condensates (BMCs) to understand the role of BMCs in brain health and disease and use this information to support development of therapeutics to treat neurological disorders. Nine projects were funded for over $3.1M, and to date, over 35 publications have resulted from this exciting program #NIHBlueprint20